Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib.

被引：0
|
作者：
van der Wekken, Anthonie J. [1 ]
Kuiper, Justine L. [2 ]
Heideman, Danielle A. M. [2 ]
Schuuring, Ed [1 ]
Timens, Wim [1 ]
Thunnissen, Erik [2 ]
Groen, Harry J. M. [1 ]
Smit, Egbert F. [2 ]
机构：
[1] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3526
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis
    Chen, Qian
    Yuan, Shumin
    Liu, Ni
    Wang, Huimin
    Shang, Xiaoling
    Ma, Xinchun
    Sun, Ying
    Wei, Chenxi
    Liu, Lian
    Wang, Xiuwen
    Liu, Yanguo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2019, 15 (25) : 2905 - 2913
  • [43] Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer
    Rounds, Amanda
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (21) : 1851 - 1855
  • [44] Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group
    Sonehara, Kei
    Kobayashi, Takashi
    Tateishi, Kazunari
    Morozumi, Nobutoshi
    Yoshiike, Fumiaki
    Hachiya, Tsutomu
    Ono, Yasushi
    Takasuna, Keiichirou
    Agatsuma, Toshihiko
    Masubuchi, Takeshi
    Matsuo, Akemi
    Tanaka, Hozumi
    Morikawa, Akio
    Hanaoka, Masayuki
    Koizumi, Tomonobu
    THORACIC CANCER, 2019, 10 (05) : 1078 - 1085
  • [45] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
  • [46] Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
    Adderley, Helen
    Ackermann, Christoph Jakob
    Califano, Raffaele
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [47] COST-MINIMIZATION ANALYSIS OF SECOND-LINE CHEMOTHERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC)
    Laurendeau, C.
    Chouaid, C.
    Florentin, V
    D'engenieres, Duchon, V
    Detournay, B.
    VALUE IN HEALTH, 2011, 14 (07) : A440 - A440
  • [48] Efficacy and Safety of Icotinib in Advanced Non-Small-Cell Lung Cancer Patients Harboring Uncommon EGFR Mutation: a Retrospective Analysis
    Yuan, Xiaobin
    Wang, Yang
    Yang, Min
    Shen, Zhilin
    Chen, Hui
    He, Xiangbo
    Ma, Yongbin
    Ding, Lieming
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (01): : 46 - 53
  • [49] Mutation Profile of EGFR Gene in Chinese Patients with Non-Small-Cell Lung Cancer (NSCLC): An Analysis of 2,666 Cases
    Lin, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1881 - S1881
  • [50] Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
    Moran, Teresa
    Taus, Alvaro
    Arriola, Edurne
    Aguado, Carlos
    Domine, Manuel
    Gomez Rueda, Ana
    Calles, Antonio
    Cedres, Susana
    Vinolas, Nuria
    Isla, Dolores
    Palmero, Ramon
    Sereno, Maria
    Diaz, Victor
    Juan, Oscar
    Marse, Raquel
    Martin Martorell, Paloma
    Sanchez Torres, Jose Miguel
    CLINICAL LUNG CANCER, 2020, 21 (05) : 428 - +
12345